Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
作者信息
Lane Deirdre A, Wood Kathryn
机构信息
From University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom (D.A.L.); Duke University School of Nursing, Durham, NC (K.W.).
出版信息
Circulation. 2015 Apr 21;131(16):e412-5. doi: 10.1161/CIRCULATIONAHA.114.012808.
Abstract
摘要
相似文献
1
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Circulation. 2015 Apr 21;131(16):e412-5. doi: 10.1161/CIRCULATIONAHA.114.012808.
2
[New clinical perspectives in the management of oral direct anticoagulant agents].
Med Clin (Barc). 2014 Feb 20;142(4):171-8. doi: 10.1016/j.medcli.2013.05.002. Epub 2013 Jul 16.
3
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Intern Med J. 2014 Jun;44(6):525-36. doi: 10.1111/imj.12448.
4
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Kardiol Pol. 2012;70(10):1053-60.
5
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
MMW Fortschr Med. 2015 Jan 19;157(1):24. doi: 10.1007/s15006-015-2575-7.
6
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Thromb Res. 2014 Oct;134(4):774-82. doi: 10.1016/j.thromres.2014.06.020. Epub 2014 Jul 6.
7
8
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006.
9
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.
10
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Thromb Haemost. 2014 May 5;111(5):981-8. doi: 10.1160/TH14-02-0118. Epub 2014 Feb 28.
引用本文的文献
1
The Effect of Direct Oral Anticoagulants on Gastric Mucosa and Helicobacter Pylori Prevalence in Dyspeptic Patients: A Retrospective Cross-Sectional Study.
Cureus. 2023 Oct 4;15(10):e46477. doi: 10.7759/cureus.46477. eCollection 2023 Oct.
2
Anticoagulation for Atrial Fibrillation in Patients with Decompensated Liver Cirrhosis: Bold and Brave?
Diagnostics (Basel). 2023 Mar 18;13(6):1160. doi: 10.3390/diagnostics13061160.
3
Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
Front Cardiovasc Med. 2021 Nov 25;8:768730. doi: 10.3389/fcvm.2021.768730. eCollection 2021.
4
Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life.
TH Open. 2021 Jun 16;5(2):e200-e210. doi: 10.1055/s-0041-1730035. eCollection 2021 Apr.
5
Hemorrhage Risk Profiles among Different Antithrombotic Regimens: Evidence from a Real-World Analysis of Postmarketing Surveillance Data.
Cardiovasc Drugs Ther. 2022 Feb;36(1):103-112. doi: 10.1007/s10557-020-07110-w. Epub 2020 Nov 23.
6
Differences In Gastrointestinal Safety Profiles Among Novel Oral Anticoagulants: Evidence From A Network Meta-Analysis.
Clin Epidemiol. 2019 Oct 1;11:911-921. doi: 10.2147/CLEP.S219335. eCollection 2019.
7
Development and validation of a questionnaire to self-assess patient knowledge of direct oral anticoagulants (KODOA-test).
Drug Healthc Patient Saf. 2018 Jul 20;10:69-77. doi: 10.2147/DHPS.S152954. eCollection 2018.
Zotero 插件